Chronic Hepatitis B – Epidemiology Insights and Forecast Report – 2020 To 2040
Chronic Hepatitis B Epidemiology Insights
Thelansis’s “Chronic
Hepatitis B Epidemiology Insights and Forecast Report – 2020 To
2040″ provides an analysis of disease burden, characterized by disease
definition, prevalence, incidence, diagnosed cases, severity, comorbidities,
and clinical manifestations. Potential patient flow dynamics in disease burden
are driven by shifts in demographic indicators and their correlation with age
and gender distribution over time. Changes in the reported cases and long-term
survival of patients may depend on diet, lifestyle, comorbid conditions, and
the availability of interventions or therapies.
Chronic
Hepatitis B Overview
Chronic Hepatitis B (CHB) infection is
characterized by the presence of Hepatitis B surface antigen (HBsAg) in the
serum for at least six months. Whereas HBsAg indicates the presence of
hepatitis B viral infection, the markers HBeAg and HBV DNA, as determined by
polymerase chain reaction (PCR) assays, are indicators of viral replication and
infectivity. Severe complications associated with chronic infection encompass
cirrhosis, liver failure, hepatocellular carcinoma, and mortality. In a
minority of cases, HBV DNA can be detected in the serum without concurrent
HBeAg presence. This phenomenon is attributed to the “pre-core” mutant, which
impedes the production and release of the “e” antigen, despite ongoing HBV DNA
replication and is associated with progressive liver disease. Following an
acute HBV infection, the risk of developing chronic hepatitis B varies with
age; less than 5% of adults develop chronic illnesses, whereas 90% of infants
do so. Significant long-term complications like chronic hepatitis, cirrhosis,
or hepatocellular carcinoma (HCC) can result from HBV transmission in children
aged five and under.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables
format and updates*:
- Access to an interactive epidemiology
platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional
findings
- Country-specific
findings
- Others*: regular updates,
customizations, epidemiologist support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the content. Countries, subpopulations, and years of forecast can be
customized as per client requirements.
Key business
questions answered:
- 20-year historical and forecast data
(2020–2040)
- Disease definition based on globally
accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage
by year and geography
- Detailed segmentation by age, gender,
subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g.,
staging/classification/severity)
Insights
driven by robust research and estimates:
- Published literature (e.g.,
peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR
datasets
- Proprietary mathematical models
(e.g., incidence-survival model;
incidence- recurrence/progression-survival model)
Read more: Chronic Hepatitis B – Epidemiology Insights and
Forecast Report – 2020 To 2040
Comments
Post a Comment